Antonella Facchinetti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5090341/publications.pdf

Version: 2024-02-01

840776 752698 38 475 11 20 citations g-index h-index papers 39 39 39 866 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	An improved method for the detection of DNA fragmentation. Journal of Immunological Methods, 1991, 136, 125-131.	1.4	84
2	Retaining the long-survive capacity of Circulating Tumor Cells (CTCs) followed by xeno-transplantation: not only from metastatic cancer of the breast but also of prostate cancer patients. Oncoscience, 2013, 1, 49-56.	2.2	52
3	Single tube liquid biopsy for advanced nonâ€small cell lung cancer. International Journal of Cancer, 2019, 144, 3127-3137.	5.1	45
4	Effect of IFN \hat{I}^2 and anti-IFN \hat{I}^2 antibodies on NK cells in multiple sclerosis patients. Journal of Neuroimmunology, 2000, 105, 91-95.	2.3	32
5	Dynamic changes of Receptor activator of nuclear factor-l [®] B expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer. Scientific Reports, 2020, 10, 1288.	3.3	25
6	Monitoring and Characterization of Circulating Tumor Cells (CTCs) in a Patient With EML4-ALK–Positive Non–Small Cell Lung Cancer (NSCLC). Clinical Lung Cancer, 2016, 17, e173-e177.	2.6	22
7	Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. Oncologist, 2021, 26, 740-750.	3.7	19
8	Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, S1346-S1358.	1.4	18
9	A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients. Translational Lung Cancer Research, 2021, 10, 80-92.	2.8	17
10	Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial. Breast Cancer Research and Treatment, 2020, $181,61-68$.	2.5	15
11	Detection and Prognostic Relevance of Circulating and Disseminated Tumour Cell in Dogs with Metastatic Mammary Carcinoma: A Pilot Study. Cancers, 2019, 11, 163.	3.7	13
12	Association between insulin-like growth factor-1 receptor (IGF1R) expression in circulating tumor cells (CTCs) and prognosis in patients with metastatic breast cancer (MBC) Journal of Clinical Oncology, 2017, 35, 1086-1086.	1.6	13
13	Protection from experimental autoimmune encephalomyelitis (EAE): non-depleting anti-CD4 mAb treatment induces peripheral T-cell tolerance to MBP in PL/J mice. Journal of Neuroimmunology, 1997, 73, 117-123.	2.3	12
14	In vivo and in vitro Death of Mature T Cells Induced by Separate Signals to CD4 and $\hat{l}\pm\hat{l}^2$ TCR. Immunobiology, 1992, 185, 380-389.	1.9	10
15	Baseline CD44v6-positive circulating tumor cells to predict first-line treatment failure in patients with metastatic colorectal cancer. Oncotarget, 2020, 11, 4115-4122.	1.8	10
16	Mechanism underlying superantigen-induced clonal deletion of mature T lymphocytes. International Immunology, 1994, 6, 983-989.	4.0	9
17	Methylation Markers in Cutaneous Melanoma: Unravelling the Potential Utility of Their Tracking by Liquid Biopsy. Cancers, 2021, 13, 6217.	3.7	9
18	A Large Number of T Lymphocytes Recognize Moloney-Murine Leukemia Virus-Induced Antigens, but a Few Mediate Long-Lasting Tumor Immunosurveillance. Journal of Immunology, 2005, 174, 5398-5406.	0.8	8

#	Article	IF	CITATIONS
19	Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer: two cases compared. Journal of Thoracic Disease, 2017, 9, \$1391-\$1396.	1.4	8
20	Mechanism of Na+/K+-ATPase activation by trypsin and kallikrein. BBA - Proteins and Proteomics, 1990, 1039, 123-129.	2.1	7
21	Functional Avidity–Driven Activation-Induced Cell Death Shapes CTL Immunodominance. Journal of Immunology, 2014, 193, 4704-4711.	0.8	7
22	Clinical significance of circulating tumor cells and cellâ€free DNA in pediatric rhabdomyosarcoma. Molecular Oncology, 2022, 16, 2071-2085.	4.6	7
23	Modulation of mitochondrial F0F1 catalysis by boundary and bulk phase phospholipids. Biochemical and Biophysical Research Communications, 1989, 158, 1013-1020.	2.1	5
24	The MBP-reactive repertoire is shaped by recognition of minor histocompatibility antigens. Journal of Neuroimmunology, 2004, 148, 154-161.	2.3	5
25	Customizing CellSearch platform. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2013, 83A, 595-598.	1.5	4
26	Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells. Melanoma Research, 2019, 29, 89-94.	1.2	4
27	Prognostic role of circulating tumor cells-CTCs in metastatic renal cell carcinoma Journal of Clinical Oncology, 2017, 35, 4568-4568.	1.6	4
28	Immune response to Moloney-murine leukemia virus-induced antigens in bone marrow. Immunology Letters, 2011, 138, 79-85.	2.5	3
29	Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor. Frontiers in Pediatrics, 2021, 9, 652583.	1.9	3
30	Apoptosis of Mature T Lymphocytes. Annals of the New York Academy of Sciences, 1992, 663, 481-482.	3.8	1
31	Liquid Biopsy in Pediatric Renal Cancer: Stage I and Stage IV Cases Compared. Diagnostics, 2020, 10, 810.	2.6	1
32	Prognostic and predictive role of CTCs and AR-V7+ CTCs expression in metastatic catrate resistant prostate cancer (mCRPC): A feasibility study Journal of Clinical Oncology, 2018, 36, 367-367.	1.6	1
33	Notes for developing a molecular test for the full characterization of circulating tumor cells. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 471-8.	2.2	1
34	Selective Lysis of Activated Cells in Oncorna Virus Infection. Scandinavian Journal of Immunology, 1997, 45, 366-370.	2.7	0
35	Adoptive transfer of Bone Marrow CD8 T lymphocytes confers full protection vs. tumor growth in M-MSV/MuLV experimental model. Immunology Letters, 2012, 144, 78-79.	2.5	0
36	Are circulating tumor cells (CTCs) a feasible tool for predicting disease recurrence and survival in nonmetastatic (M0) colorectal cancer (CRC)?. Journal of Clinical Oncology, 2015, 33, 650-650.	1.6	0

#	Article	IF	CITATIONS
37	Abstract 387: Non small cell lung cancer and circulating tumor cell: A different expression of EpCam and cytokeratins. , 2015, , .		O
38	Abstract 379: Circulating tumor cells (CTCs) in clinically localized prostate cancer (PCa): searching a prognostic tool., 2015,,.		0